Immune cell-mediated features of non-alcoholic steatohepatitis
T Huby, EL Gautier - Nature reviews immunology, 2022 - nature.com
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
Hepatic inflammatory responses in liver fibrosis
Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …
Liver macrophages in tissue homeostasis and disease
O Krenkel, F Tacke - Nature Reviews Immunology, 2017 - nature.com
Macrophages represent a key cellular component of the liver, and are essential for
maintaining tissue homeostasis and ensuring rapid responses to hepatic injury. Our …
maintaining tissue homeostasis and ensuring rapid responses to hepatic injury. Our …
Targeting hepatic macrophages to treat liver diseases
F Tacke - Journal of hepatology, 2017 - Elsevier
Our view on liver macrophages in the context of health and disease has been reformed by
the recognition of a remarkable heterogeneity of phagocytes in the liver. Liver macrophages …
the recognition of a remarkable heterogeneity of phagocytes in the liver. Liver macrophages …
[HTML][HTML] Excess body weight: Novel insights into its roles in obesity comorbidities
Excess body weight is a global health problem due to sedentary lifestyle and unhealthy diet,
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …
Molecular pathways of nonalcoholic fatty liver disease development and progression
F Bessone, MV Razori, MG Roma - Cellular and Molecular Life Sciences, 2019 - Springer
Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …
SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection
Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …
Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice
B Xu, M Jiang, Y Chu, W Wang, D Chen, X Li… - Journal of …, 2018 - Elsevier
Background & Aims Gasdermin D (GSDMD)-executed programmed necrosis is involved in
inflammation and controls interleukin (IL)-1β release. However, the role of GSDMD in non …
inflammation and controls interleukin (IL)-1β release. However, the role of GSDMD in non …
Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances
Non‐alcoholic fatty liver disease (NAFLD) is a continuous spectrum of diseases
characterized by excessive lipid accumulation in hepatocytes. NAFLD progresses from …
characterized by excessive lipid accumulation in hepatocytes. NAFLD progresses from …
LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis
DP Li, L Huang, RR Kan, XY Meng, SY Wang… - Nature …, 2023 - nature.com
Inhibition of immunocyte infiltration and activation has been suggested to effectively
ameliorate nonalcoholic steatohepatitis (NASH). Paired immunoglobulin-like receptor B …
ameliorate nonalcoholic steatohepatitis (NASH). Paired immunoglobulin-like receptor B …